AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10197572 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 71
Study 7750592 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (1 mL/kg 95% ethanol)
Number of subjects: 12
Study 7750592 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate placebo punch
Number of subjects: 12
Study 2328553 — intervention group
Group type: EXPERIMENTAL
Intervention: WEB-2086 (40 mg)
Number of subjects: 12
Study 2328553 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6931307 — intervention group
Group type: EXPERIMENTAL
Intervention: MeCCNU and VCR (vincristine)
Number of subjects: 40
Study 6931307 — intervention group
Group type: EXPERIMENTAL
Intervention: MeCCNU and DTIC (5‐(3,3‐dimethyl‐1‐triazeno)‐imidazole‐4‐carboxamide)
Number of subjects: 40
Study 6931307 — intervention group
Group type: EXPERIMENTAL
Intervention: MeCCNU, DTIC, and VCR
Number of subjects: 40
Study 6931307 — intervention group
Group type: EXPERIMENTAL
Intervention: MeCCNU and B‐2‐deoxythioguanosine
Number of subjects: 40
Study 6931307 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy containing MeCCNU
Number of subjects: 40
Study 30985546 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal viral load >10,000 copies/mL
Number of subjects: 2275
Study 30985546 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal viral load <1000 copies/mL
Number of subjects: 2275
Study 30985546 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal viral load 1000.1-10,000 copies/mL
Number of subjects: 2275
Study 30985546 — intervention group
Group type: EXPERIMENTAL
Intervention: Food shortage
Number of subjects: 2275
Study 30985546 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexually transmitted infection (STI) in the past year
Number of subjects: 2275
Study 30985546 — intervention group
Group type: EXPERIMENTAL
Intervention: History of herpes zoster
Number of subjects: 2275
Study 30985546 — intervention group
Group type: EXPERIMENTAL
Intervention: History of tuberculosis
Number of subjects: 2275
Study 29126030 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (1g/day)
Number of subjects: 50
Study 29126030 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 50
Study 25887884 — intervention group
Group type: EXPERIMENTAL
Intervention: Short stitch suture technique
Number of subjects: 468
Study 25887884 — intervention group
Group type: COMPARATOR
Intervention: Long stitch suture technique
Number of subjects: 468
Study 23896581 — intervention group
Group type: EXPERIMENTAL
Intervention: 2010-2011 seasonal trivalent influenza vaccine (TIV) manufactured by GlaxoSmithKline
Number of subjects: 900
Study 23896581 — intervention group
Group type: EXPERIMENTAL
Intervention: 2010-2011 seasonal trivalent influenza vaccine (TIV) manufactured by Sanofi Pasteur
Number of subjects: 900
Study 23896581 — intervention group
Group type: EXPERIMENTAL
Intervention: 2010-2011 seasonal trivalent influenza vaccine (TIV) manufactured by Sinovac Biotech
Number of subjects: 900
Study 23896581 — intervention group
Group type: COMPARATOR
Intervention: 2010-2011 seasonal trivalent influenza vaccine (TIV)
Number of subjects: 900
Study 20801515 — intervention group
Group type: EXPERIMENTAL
Intervention: Confocal microscopy
Number of subjects: 146
Study 19706087 — intervention group
Group type: EXPERIMENTAL
Intervention: Emollient application alone
Number of subjects: 10
Study 19706087 — intervention group
Group type: EXPERIMENTAL
Intervention: Bathing with immediate emollient application
Number of subjects: 10
Study 19706087 — intervention group
Group type: EXPERIMENTAL
Intervention: Bathing and delayed emollient application
Number of subjects: 10
Study 19706087 — intervention group
Group type: EXPERIMENTAL
Intervention: Bathing alone
Number of subjects: 10
Study 19706087 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination bathing and emollient application regimens
Number of subjects: 10
Study 19706087 — intervention group
Group type: COMPARATOR
Intervention: Bathing without moisturizer
Number of subjects: 10
Study 19706087 — intervention group
Group type: EXPERIMENTAL
Intervention: Bathing followed by moisturizer application
Number of subjects: 10
Study 17920918 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg daily)
Number of subjects: 41276
Study 17920918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41276
Study 14688176 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin plus anastrozole for 6 months
Number of subjects: 80
Study 14688176 — intervention group
Group type: COMPARATOR
Intervention: Goserelin alone for 6 months
Number of subjects: 80
Study 14688176 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin plus anastrozole
Number of subjects: 80
Study 14688176 — intervention group
Group type: COMPARATOR
Intervention: Goserelin alone
Number of subjects: 80
Study 11207037 — intervention group
Group type: EXPERIMENTAL
Intervention: New formula for estimating GFR using patient characteristics
Number of subjects: 62
Study 11207037 — intervention group
Group type: COMPARATOR
Intervention: Cockcroft and Gault formula
Number of subjects: 62
Study 11207037 — intervention group
Group type: COMPARATOR
Intervention: Jelliffe formula
Number of subjects: 62
Study 9715553 — intervention group
Group type: EXPERIMENTAL
Intervention: Twins
Number of subjects: 42
Study 9715553 — intervention group
Group type: COMPARATOR
Intervention: Normal singleton controls
Number of subjects: 42
Study 9715553 — intervention group
Group type: EXPERIMENTAL
Intervention: LBW twins
Number of subjects: 42
Study 9715553 — intervention group
Group type: COMPARATOR
Intervention: Matched high risk singletons
Number of subjects: 42
Study 8373942 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 ml/kg alcohol
Number of subjects: 30
Study 8373942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 3538520 — intervention group
Group type: EXPERIMENTAL
Intervention: argon laser photocoagulation
Number of subjects: 38
Study 31694439 — intervention group
Group type: EXPERIMENTAL
Intervention: GOLD 2 patients
Number of subjects: 542
Study 31694439 — intervention group
Group type: EXPERIMENTAL
Intervention: GOLD 3 patients
Number of subjects: 542
Study 31694439 — intervention group
Group type: COMPARATOR
Intervention: No assigned GP
Number of subjects: 542
Study 31694439 — intervention group
Group type: COMPARATOR
Intervention: No contact with COPD nurse in the past 12 months
Number of subjects: 542
Study 31694439 — intervention group
Group type: COMPARATOR
Intervention: Continuity in patient-GP consultations
Number of subjects: 542
Study 31694439 — intervention group
Group type: COMPARATOR
Intervention: Contact with a COPD nurse
Number of subjects: 542
Study 29146401 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib 240 mg/day for 1 year
Number of subjects: 2840
Study 29146401 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2840
Study 29146401 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib
Number of subjects: 2840
Study 25990305 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous bolus of MRA therapy (potassium canrenoate 200 mg) followed by oral spironolactone 50 mg once daily for 3 months
Number of subjects: 150
Study 25990305 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo prior to PPCI followed by matching placebo for 3 months
Number of subjects: 150
Study 23053125 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycogen (LG) exercise
Number of subjects: 10
Study 23053125 — intervention group
Group type: COMPARATOR
Intervention: Normal glycogen (NG) exercise
Number of subjects: 10
Study 21604965 — intervention group
Group type: EXPERIMENTAL
Intervention: Good practice intervention for childhood obesity (8 hours contact over 26 weeks, group based)
Number of subjects: 107
Study 21604965 — intervention group
Group type: EXPERIMENTAL
Intervention: Good practice intervention for childhood obesity
Number of subjects: 107
Study 21604965 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 107
Study 19380329 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 90 mg
Number of subjects: 34701
Study 19380329 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 60 mg
Number of subjects: 34701
Study 19380329 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 150 mg
Number of subjects: 34701
Study 19380329 — intervention group
Group type: EXPERIMENTAL
Intervention: History of CHF
Number of subjects: 34701
Study 19380329 — intervention group
Group type: EXPERIMENTAL
Intervention: Age > or = 65 years
Number of subjects: 34701
Study 19380329 — intervention group
Group type: EXPERIMENTAL
Intervention: History of hypertension
Number of subjects: 34701
Study 19380329 — intervention group
Group type: EXPERIMENTAL
Intervention: History of diabetes
Number of subjects: 34701
Study 17005084 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) 100 Hz
Number of subjects: 72
Study 17005084 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) 2 Hz
Number of subjects: 72
Study 17005084 — intervention group
Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 72
Study 15552355 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous presentation of items for selection
Number of subjects: 0
Study 15552355 — intervention group
Group type: COMPARATOR
Intervention: Sequential presentation of items for selection
Number of subjects: 0
Study 15552355 — intervention group
Group type: EXPERIMENTAL
Intervention: High memory spans
Number of subjects: 0
Study 15552355 — intervention group
Group type: EXPERIMENTAL
Intervention: Low memory spans
Number of subjects: 0
Study 10711616 — intervention group
Group type: EXPERIMENTAL
Intervention: Active chlorhexidine chip plus scaling and root planing (SRP)
Number of subjects: 45
Study 10711616 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) alone
Number of subjects: 45
Study 10711616 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) plus placebo chip
Number of subjects: 45
Study 9371930 — intervention group
Group type: EXPERIMENTAL
Intervention: Optic neuritis treatment
Number of subjects: 388
Study 9371930 — intervention group
Group type: EXPERIMENTAL
Intervention: No MRI lesions
Number of subjects: 388
Study 9371930 — intervention group
Group type: EXPERIMENTAL
Intervention: Three or more MRI lesions
Number of subjects: 388
Study 9371930 — intervention group
Group type: EXPERIMENTAL
Intervention: No brain MRI lesions and no history of neurologic symptoms or optic neuritis in the fellow eye
Number of subjects: 388
Study 1287831 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated circuit with 50% reduction of systemic heparin bolus
Number of subjects: 20
Study 1287831 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard heparin treatment)
Number of subjects: 20
Study 4026691 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy
Number of subjects: 122
Study 4026691 — intervention group
Group type: COMPARATOR
Intervention: Betahistine (vasoactive substance)
Number of subjects: 122
Study 12281505 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG injections (250 IU/day i.m.) for 21 days in OC users
Number of subjects: 82
Study 12281505 — intervention group
Group type: COMPARATOR
Intervention: 500 kcal reduction diet for 28 days
Number of subjects: 82
Study 12281505 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG injections (250 IU/day i.m.)
Number of subjects: 82
Study 31379301 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior-to-posterior (AP) non-thrust manipulation (NTM)
Number of subjects: 43
Study 31379301 — intervention group
Group type: COMPARATOR
Intervention: Lateral (LAT) non-thrust manipulation (NTM)
Number of subjects: 43
Study 31379301 — intervention group
Group type: EXPERIMENTAL
Intervention: Both AP and LAT NTM
Number of subjects: 43
Study 31379301 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting systolic blood pressure (SBP)
Number of subjects: 43
Study 31060795 — intervention group
Group type: EXPERIMENTAL
Intervention: Interstitial brachytherapy
Number of subjects: 0
Study 31060795 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing trials
Number of subjects: 0
Study 29097325 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg dezocine
Number of subjects: 390
Study 29097325 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg dezocine
Number of subjects: 390
Study 29097325 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg dezocine
Number of subjects: 390
Study 29097325 — intervention group
Group type: COMPARATOR
Intervention: Control group (0.1 mg/kg)
Number of subjects: 390
Study 25331375 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Low Calorie Diet (VLCD) for 6 weeks
Number of subjects: 34
Study 25331375 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese participants
Number of subjects: 34
Study 25331375 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-obese participants)
Number of subjects: 34
Study 25331375 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body fat oxidation
Number of subjects: 34
Study 25331375 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body carbohydrate oxidation
Number of subjects: 34
Study 24057149 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amantadine
Number of subjects: 42
Study 24057149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 21463139 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel plus prednisone
Number of subjects: 0
Study 21463139 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel-based therapy
Number of subjects: 0
Study 18261733 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 5804
Study 18261733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5804
Study 17001217 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking prevalence
Number of subjects: 2989
Study 17001217 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension prevalence
Number of subjects: 2989
Study 17001217 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity prevalence
Number of subjects: 2989
Study 17001217 — intervention group
Group type: EXPERIMENTAL
Intervention: High total cholesterol prevalence
Number of subjects: 2989
Study 17001217 — intervention group
Group type: EXPERIMENTAL
Intervention: High low-density lipoprotein (LDL) cholesterol prevalence
Number of subjects: 2989
Study 17001217 — intervention group
Group type: EXPERIMENTAL
Intervention: Low high-density lipoprotein (HDL) cholesterol prevalence
Number of subjects: 2989
Study 17001217 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes prevalence
Number of subjects: 2989
Study 17001217 — intervention group
Group type: EXPERIMENTAL
Intervention: Population attributable risks for high total cholesterol, hypertension, and large waist-to-hip ratio
Number of subjects: 2989
Study 12940398 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-mediated cognitive-behavioral (GMCB) intervention
Number of subjects: 147
Study 12940398 — intervention group
Group type: COMPARATOR
Intervention: Standard exercise therapy
Number of subjects: 147
Study 10852328 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate
Number of subjects: 32
Study 10852328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 9327311 — intervention group
Group type: EXPERIMENTAL
Intervention: fentanyl infusion + diazepam + sodium nitroprusside (SNP)
Number of subjects: 66
Study 9327311 — intervention group
Group type: EXPERIMENTAL
Intervention: fentanyl infusion + isoflurane
Number of subjects: 66
Study 9327311 — intervention group
Group type: COMPARATOR
Intervention: fentanyl infusion + diazepam
Number of subjects: 66
Study 7968323 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium with a priming dose of 0.1 mg/kg followed by 0.09 mg/kg (Gp1)
Number of subjects: 90
Study 7968323 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium with a priming dose of 0.1 mg/kg followed by 0.14 mg/kg (Gp2)
Number of subjects: 90
Study 7968323 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium with a priming dose of 0.1 mg/kg followed by 0.19 mg/kg (Gp3)
Number of subjects: 90
Study 7968323 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium without a priming dose followed by 0.1 mg/kg (Gp4)
Number of subjects: 90
Study 7968323 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium without a priming dose followed by 0.15 mg/kg (Gp5)
Number of subjects: 90
Study 7968323 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium without a priming dose followed by 0.2 mg/kg (Gp6)
Number of subjects: 90
Study 3897470 — intervention group
Group type: EXPERIMENTAL
Intervention: BCOP (cyclophosphamide, vincristine, prednisone plus BCNU)
Number of subjects: 296
Study 3897470 — intervention group
Group type: COMPARATOR
Intervention: CHOP (doxorubicin)
Number of subjects: 296
Study 3897470 — intervention group
Group type: EXPERIMENTAL
Intervention: BCOP
Number of subjects: 296
Study 3897470 — intervention group
Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 296
Study 31124719 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone communication and task prioritization training (group A)
Number of subjects: 50
Study 31124719 — intervention group
Group type: COMPARATOR
Intervention: Untrained final year students (group B)
Number of subjects: 50
Study 31124719 — intervention group
Group type: EXPERIMENTAL
Intervention: Training session on telephone communication and task prioritization (group A)
Number of subjects: 50
Study 28190719 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-component smoking cessation intervention (physician advice, nicotine replacement therapy, and telephone-based quitline referral)
Number of subjects: 156
Study 28190719 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 156
Study 28190719 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician advice
Number of subjects: 156
Study 28190719 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy
Number of subjects: 156
Study 26227096 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg linezolid infusion over 0.5 hours
Number of subjects: 12
Study 26227096 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg linezolid infusion over 2 hours
Number of subjects: 12
Study 26227096 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg linezolid infusion over 4 hours
Number of subjects: 12
Study 24119833 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 2 mg by mouth
Number of subjects: 33
Study 24119833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 21091391 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-release melatonin (PRM; Circadin 2 mg)
Number of subjects: 930
Study 21091391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 930
Study 19176534 — intervention group
Group type: EXPERIMENTAL
Intervention: Antepartum continuous epidural therapy (ACET) with 0.04, 0.06, 0.08, and 0.1% ropivacaine at 10 ml h(‐1) for 24 h.
Number of subjects: 10
Study 19176534 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) after ACET.
Number of subjects: 10
Study 19176534 — intervention group
Group type: EXPERIMENTAL
Intervention: Antepartum continuous epidural therapy (ACET) with 0.1% ropivacaine until delivery.
Number of subjects: 10
Study 18173095 — intervention group
Group type: EXPERIMENTAL
Intervention: OP-lycopene (8 mg lycopene/day for 2 weeks)
Number of subjects: 20
Study 18173095 — intervention group
Group type: EXPERIMENTAL
Intervention: non-OP-lycopene (8 mg lycopene/day for 2 weeks)
Number of subjects: 20
Study 18173095 — intervention group
Group type: EXPERIMENTAL
Intervention: OP-lycopene
Number of subjects: 20
Study 18173095 — intervention group
Group type: COMPARATOR
Intervention: OP-placebo
Number of subjects: 20
Study 18173095 — intervention group
Group type: COMPARATOR
Intervention: non-OP-placebo
Number of subjects: 20
Study 15469204 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (50 mg/day titrated to 500 mg/day, maintained or increased to 750 mg/day)
Number of subjects: 12
Study 12804167 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy (specifics not provided)
Number of subjects: 0
Study 12804167 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9802253 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinetic Energy (KE) display
Number of subjects: 27
Study 9802253 — intervention group
Group type: EXPERIMENTAL
Intervention: Time Headway (TH) display
Number of subjects: 27
Study 9802253 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study 7653005 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Number of subjects: 0
Study 2096128 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg cimetidine twice daily
Number of subjects: 40
Study 2096128 — intervention group
Group type: COMPARATOR
Intervention: 800 mg cimetidine once daily (bedtime)
Number of subjects: 40
Study 626718 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned delivery group
Number of subjects: 264
Study 626718 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 264
Study 626718 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 264
Study 30426133 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical inspiration and expiration exercise
Number of subjects: 36
Study 30426133 — intervention group
Group type: COMPARATOR
Intervention: Conventional dysphagia therapy
Number of subjects: 36
Study 28976450 — intervention group
Group type: EXPERIMENTAL
Intervention: Always experienced simulated mortality (always death)
Number of subjects: 50
Study 28976450 — intervention group
Group type: COMPARATOR
Intervention: Never experienced simulated mortality (never death)
Number of subjects: 50
Study 28976450 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable simulated mortality based on performance (variable death)
Number of subjects: 50
Study 25335860 — intervention group
Group type: EXPERIMENTAL
Intervention: Netazepide
Number of subjects: 30
Study 25335860 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Number of subjects: 30
Study 25335860 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of netazepide and rabeprazole
Number of subjects: 30
Study 25335860 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 30
Study 23396459 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to mobile phone electromagnetic fields for 60 minutes
Number of subjects: 0
Study 21258269 — intervention group
Group type: EXPERIMENTAL
Intervention: Intimate partner violence (IPV)
Number of subjects: 717